Renibus Therapeutics

Southlake Biotech Renibus Therapeutics Garners $33M in Bridge Financing

by | Dec 8, 2022
Southlake-based Renibus Therapeutics—a clinical-stage biotech company developing innovative products for cardiorenal diseases—has received $33 million in bridge financing to help it advance three drugs in its pipeline. The drugs are currently in various phases of trials.
MORE
Follow the Money: P10 Acquires California Investment Firm, SmartMoving Lands $41.5M, and More
by | Aug 29, 2022
In this week’s North Texas deal flow, you’ll also find news about Biotech Renibus Therapeutics raising $8.48M to fight cardio-renal disease; Deposits raising $5M for its plug-and-play financial services platform; Lion Real Estate Group targeting multifamily properties in the Sun Belt with a $200M fund, and more.
MORE
Follow the Money: Southlake Biotech Raises $14.9M, American Airlines Invests in Innovative Engine Maker, and More
by | Aug 8, 2022
Plus: 7-Eleven acquires last-mile delivery startup; American Heart Association invests in $43M healthcare innovation fund; Fort Worth real estate investors raise $32.4M for new fund; Dallas College Lands $8.8M to boost biotech workforce; UT Southwestern researchers land funding for hypothermia therapy study; and more North Texas deals.
MORE
From right: DRC's Jorge Varela (far right) moderated a panel of industry experts including biotech C-level executive Hua Tu, Health Wildcatters CEO and co-founder Hubert Zajicek, and LH Capital Director Matt Crommett.
‘From a Trickle to a Waterfall’: How Biotech’s Flow is Growing in DFW
by | May 24, 2022
"It takes time" to establish a track record, Jorge Varela says, and the region is starting to see a series of biotech successes and spinoffs that will elevate the region's profile as a biotech hub.

According to a panel of experts at Urban Land Institute's 2022 spring meeting, here are factors drawing biotech to DFW.
MORE

With New Funding and CEO, This Southlake Biotech is Looking to Solve Kidney Disease

by | Feb 16, 2022
Renibus Therapeutics, which focuses on treatments for acute and chronic kidney diseases, announced closing a $35 million Series A funding round. Its new CEO, Frank Stonebanks, says "Renibus has arrived at a critical inflection point in its commitment to transform the prevention and treatment of kidney diseases."
MORE
funding investment
Follow the Money: Latticework Capital Raises $120M, Renibus Therapeutics Gets $3.37M, HMS Buys VitreosHealth
by | Sep 26, 2019
In this weekly roundup of funding, merger, and acquisition activity involving companies in North Texas, you’ll also find news about Fetch, Figable, Stealth Monitoring, Solo Stove, BP Energy Partners, Integrity Marketing, a360inc, and more.
MORE